Cargando…
Long-Term Efficacy and Safety of Ultra Rapid Lispro (URLi) in Adults with Type 1 Diabetes: The PRONTO-T1D Extension
INTRODUCTION: The PRONTO-T1D study, which evaluated the efficacy and safety of ultra rapid lispro (URLi) versus lispro in adults with type 1 diabetes (T1D), met the primary endpoint of noninferiority of HbA1c change from baseline compared to lispro at 26 weeks. We present results of an additional 26...
Autores principales: | Bue-Valleskey, Juliana, Klaff, Leslie, Cho, Jang Ik, Dellva, Mary Anne, Schloot, Nanette C., Tobian, Janet, Miura, Junnosuke, Dahl, Dominik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7846637/ https://www.ncbi.nlm.nih.gov/pubmed/33458803 http://dx.doi.org/10.1007/s13300-020-00987-8 |
Ejemplares similares
-
Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study
por: Klaff, Leslie, et al.
Publicado: (2020) -
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy
por: Malecki, Maciej T., et al.
Publicado: (2020) -
Efficacy and safety of ultra‐rapid lispro versus lispro in children and adolescents with type 1 diabetes: The PRONTO‐Peds trial
por: Wadwa, R. Paul, et al.
Publicado: (2022) -
Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog(®) in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis
por: Miura, Junnosuke, et al.
Publicado: (2020) -
Long-term Efficacy and Safety of Ultra Rapid Lispro in Japanese Patients With Type 1 Diabetes: Subpopulation Analysis of the 52-Week PRONTO-T1D Study
por: Miura, Junnosuke, et al.
Publicado: (2021)